AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toenjes, K. A.
Right arrow Articles by Johnson, D. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toenjes, K. A.
Right arrow Articles by Johnson, D. I.
Antimicrobial Agents and Chemotherapy, March 2005, p. 963-972, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.963-972.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Small-Molecule Inhibitors of the Budded-to-Hyphal-Form Transition in the Pathogenic Yeast Candida albicans

Kurt A. Toenjes,1 Suzanne M. Munsee,1 Ashraf S. Ibrahim,2 Rachel Jeffrey,1 John E. Edwards Jr.,2 and Douglas I. Johnson1*

Department of Microbiology and Molecular Genetics and Markey Center for Molecular Genetics, University of Vermont, Burlington, Vermont,1 Division of Infectious Diseases, St. John's Cardiovascular Research Center, Harbor-UCLA Research and Education Institute, Torrance, California2

Received 5 August 2004/ Returned for modification 20 August 2004/ Accepted 22 October 2004

The pathogenic yeast Candida albicans can exist in multiple morphological states, including budded, pseudohyphal, and true hyphal forms. The ability to convert between the budded and hyphal forms, termed the budded-to-hyphal-form transition, is important for virulence and is regulated by multiple environmental and cellular signals. To identify inhibitors of this morphological transition, a microplate-based morphological assay was developed. With this assay, the known actin-inhibiting drugs latrunculin-A and jasplakinolide were shown to inhibit the transition in a dose-dependent and reversible manner. Five novel small molecules that reversibly inhibited the transition and hyphal elongation without affecting budded growth were identified. These molecules inhibited hyphal growth induced by Spider, Lee's, M199 pH 8, and 10% serum-containing media, with two molecules having a synergistic effect. The molecules also differentially affected the hyphal form-specific gene expression of HWP1 and endocytosis without disrupting the actin cytoskeleton or septin organization. Structural derivatives of one of the molecules were more effective inhibiters than the original molecule, while other derivatives had decreased efficacies. Several of the small molecules were able to reduce C. albicans-dependent damage to endothelial cells by inhibiting the budded-to-hyphal-form transition. These studies substantiated the effectiveness of the morphological assay and identified several novel molecules that, by virtue of their ability to inhibit the budded-to-hyphal-form transition, may be exploited as starting points for effective antifungal therapeutics in the future.


* Corresponding author. Mailing address: Department of Microbiology and Molecular Genetics, 202 Stafford Hall, 95 Carrigan Dr., University of Vermont, Burlington, VT 05405. Phone: (802) 656-8203. Fax: (802) 656-8749. E-mail: Douglas.Johnson{at}uvm.edu.


Antimicrobial Agents and Chemotherapy, March 2005, p. 963-972, Vol. 49, No. 3
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.3.963-972.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2005 by the American Society for Microbiology. All rights reserved.